[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kovacs et al., 2013 - Google Patents

Neuropathology of the hippocampus in FTLD‐Tau with Pick bodies: a study of the BrainNet Europe Consortium

Kovacs et al., 2013

View PDF
Document ID
900349865491510616
Author
Kovacs G
Rozemuller A
van Swieten J
Gelpi E
Majtenyi K
Al‐Sarraj S
Troakes C
Bódi I
King A
Hortobágyi T
Esiri M
Ansorge O
Giaccone G
Ferrer I
Arzberger T
Bogdanovic N
Nilsson T
Leisser I
Alafuzoff I
Ironside J
Kretzschmar H
Budka H
Publication year
Publication venue
Neuropathology and applied neurobiology

External Links

Snippet

GG Kovacs, AJM Rozemuller, JC van Swieten, E. Gelpi, K. Majtenyi, S. Al‐Sarraj, C. Troakes, I. Bódi, A. King, T. Hortobágyi, MM Esiri, O. Ansorge, G. Giaccone, I. Ferrer, T. Arzberger, N. Bogdanovic, T. Nilsson, I. Leisser, I. Alafuzoff, JW Ironside, H. Kretzschmar and …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Similar Documents

Publication Publication Date Title
Kovacs et al. Neuropathology of the hippocampus in FTLD‐Tau with Pick bodies: a study of the BrainNet Europe Consortium
Kovacs et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series
Kovacs Invited review: neuropathology of tauopathies: principles and practice
Kovacs et al. Dura mater is a potential source of Aβ seeds
Kovacs et al. A peculiar constellation of tau pathology defines a subset of dementia in the elderly
Dickson Neuropathology of non-Alzheimer degenerative disorders
Lim et al. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies
Kovacs et al. Tau pathology in Creutzfeldt‐Jakob disease revisited
Hark et al. Pulse-chase proteomics of the App knockin mouse models of Alzheimer’s disease reveals that synaptic dysfunction originates in presynaptic terminals
Colom-Cadena et al. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies
Lace et al. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study
Josephs et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration
Uchikado et al. Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy
Kovacs et al. Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy
Davidson et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset Alzheimer’s disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype
Shi et al. Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation
Blennow CSF biomarkers for mild cognitive impairment
Mikolaenko et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA)
Yoshida Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies
Lue et al. Biochemical increase in phosphorylated alpha‐synuclein precedes histopathology of Lewy‐type synucleinopathies
Falzone et al. Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects
Kovacs Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?
Obi et al. Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies
Moreno et al. A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques
Dickson Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases